$1.9M Grant Awarded for Study on How Fat Cells Help Myeloma Cells Resist Treatment
A new research project aiming to better understand how fat cells help multiple myeloma cells resist treatment has won a $1.9 million grant from…
News
Sarclisa Triple Combo Prolongs Life Without Disease Progression in Some Myeloma Patients, Interim Data Show
A combination of Sarclisa (isatuximab) plus standard Kyprolis (carfilzomib) and dexamethasone treatment significantly delays disease progression or death in people with relapsed or…
FDA Office Favors Antibody-drug Conjugate for Advanced Multiple Myeloma
An office of the U.S. Food and Drug Administration (FDA) has recommended that belantamab mafodotin, GlaxoSmithKline’s investigational antibody-drug conjugate, be approved for…
GNS Healthcare Launches Computer Model of Disease Progression, Treatment Responses in Myeloma
A computer program developed by GNS Healthcare could be used to model and predict disease progression and response to treatment in people with…
Reolysin-Kyprolis Combo Elicits Promising Clinical Responses in Phase 1B Trial
When given in combination with Kyprolis (carfilzomib), the investigative therapy Reolysin (pelareorep) elicits a strong inflammatory response — and promising clinical responses…
FDA Accelerated Approval of Melflufen Sought for Hard-to-treat Myeloma Patients
Oncopeptides has submitted a new drug application to the U.S. Food and Drug Administration (FDA) requesting the accelerated approval of melflufen (melphalan…
1,066 Myeloma Patients Answer HealthTree Survey of COVID-19’s Effects
Over some four weeks, 1,066 people with multiple myeloma took part in a survey sponsored by HealthTree to better understand how COVID-19 is affecting life…
FDA’s New ‘Project Patient Voice’ to Share Symptoms Data From Cancer Trials
The U.S. Food and Drug Administration (FDA) has launched an initiative called Project Patient Voice to create a publicly available information bank describing…
Ninlaro Maintenance Therapy Improves Survival in Patients Not Given ASCT, Trial Shows
First-line maintenance therapy with Ninlaro (ixazomib) significantly delays disease progression or death in adults with multiple myeloma who had not been initially treated with…
Oncopeptides Reports Positive Results from HORIZON Trial of Melflufen Combo
The combination therapy of melflufen (melphalan flufenamide) and dexamethasone continues to be safe and to elicit deep and durable responses in hard-to-treat patients…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML